Singapore has one of Asia’s fastest-growing biopharma industries, with forecasts revealing a two fold trajectory of $68.7 billion in market size by the year 2029, and the country’s healthcare spending is expected to contribute to 5.9% of its GDP and is rising.
The Singapore Medicines Act governs the promotion of medicines, and the enforcement of these regulations is governed by the Health Sciences Authority (HSA) and the Singapore Association of Pharmaceutical Industries (SAPI). While there is no difference in the regulations for consumer and client publications, general regulations still apply. General principles include truthfulness, accuracy and use of scientific data.
Sign up to get the guides
Select the guides you wish to download